Adial Secures European Path for Addiction Drug with Molteni Collaboration
Event summary
- Adial Pharmaceuticals has signed a collaboration framework agreement with Molteni Farmaceutici for the commercialization of AD04 in Europe.
- The agreement anticipates potential royalties and milestones totaling nearly $60 million upon execution of a definitive agreement.
- Molteni has an exclusive period to evaluate the project and conduct due diligence before finalizing the agreement.
- The deal represents Adial’s first step toward establishing a European commercial pathway for AD04.
The big picture
This collaboration represents a significant shift for Adial, marking its entry into the European market and a move away from solely relying on U.S. commercialization. The deal, potentially worth $60 million, underscores the growing interest in genetically targeted therapies for addiction, a market with substantial unmet need. Molteni’s established European infrastructure and SUD treatment expertise provide Adial with a valuable partner to navigate the complexities of the European regulatory landscape.
What we're watching
- Deal Execution
- The success of this collaboration hinges on the finalization of the definitive agreement, which could be impacted by ongoing due diligence and negotiation of terms.
- Clinical Progress
- The $60 million potential value is contingent on AD04 progressing through clinical development, highlighting the importance of upcoming Phase 3 trial results.
- Genetic Targeting
- Adial’s genotype-driven development strategy requires continued validation and adoption by physicians, which will influence the drug’s commercial uptake.
Related topics